KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Pacira BioSciences (PCRX) Shares Outstanding (2016 - 2026)

Pacira BioSciences has reported Shares Outstanding over the past 17 years, most recently at $39.3 million for Q1 2026.

  • For Q1 2026, Shares Outstanding fell 16.58% year-over-year to $39.3 million; the TTM value through Mar 2026 reached $39.3 million, down 16.58%, while the annual FY2025 figure was $41.1 million, 12.66% down from the prior year.
  • Shares Outstanding for Q1 2026 was $39.3 million at Pacira BioSciences, down from $41.1 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $47.7 million in Q3 2025 and troughed at $39.3 million in Q1 2026.
  • A 5-year average of $45.8 million and a median of $46.4 million in 2023 define the central range for Shares Outstanding.
  • Biggest five-year swings in Shares Outstanding: increased 3.07% in 2022 and later decreased 16.58% in 2026.
  • Year by year, Shares Outstanding stood at $45.9 million in 2022, then increased by 1.2% to $46.5 million in 2023, then increased by 1.28% to $47.1 million in 2024, then decreased by 12.66% to $41.1 million in 2025, then fell by 4.4% to $39.3 million in 2026.
  • Business Quant data shows Shares Outstanding for PCRX at $39.3 million in Q1 2026, $41.1 million in Q4 2025, and $43.0 million in Q3 2025.